Use of biologics for psoriasis in solid organ transplant recipients.
Australas J Dermatol
; 65(3): 276-279, 2024 May.
Article
en En
| MEDLINE
| ID: mdl-38623950
ABSTRACT
Biologics have significantly advanced the treatment of inflammatory disorders, including psoriasis. However, their use in immunosuppressed patients, such as those with solid-organ transplants, is less understood. These patients often face dermatological issues, but inflammatory skin diseases are rare due to their immunosuppressive treatments. Our study aims to assess biologics' effectiveness in such immunocompromised patients. We report a case from our institution of a 29-year-old man with a history of psoriasis, who underwent a kidney transplant and later developed erythroderma. He did not respond to traditional treatments and was successfully treated with adalimumab, leading to the discontinuation of MMF. We also reviewed literature in solid organ transplant patients with psoriasis. Our findings, based on 10 articles, indicate a cautious approach to using biologics in this group, with further research needed for efficacy and safety.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Psoriasis
/
Productos Biológicos
/
Trasplante de Riñón
/
Adalimumab
Límite:
Adult
/
Humans
/
Male
Idioma:
En
Revista:
Australas J Dermatol
Año:
2024
Tipo del documento:
Article
País de afiliación:
Irlanda